featured
Palbociclib ± the Endocrine Therapy Received Before Disease Progression for ER+/HER2− Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Palbociclib as Single Agent or in Combination With the Endocrine Therapy Received Before Disease Progression for Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: TREnd Trial
Ann. Oncol 2018 Jun 11;[EPub Ahead of Print], L Malorni, G Curigliano, AM Minisini, S Cinieri, CA Tondini, K D'Hollander, G Arpino, A Bernardo, A Martignetti, C Criscitiello, F Puglisi, M Pestrin, G Sanna, E Moretti, E Risi, C Biagioni, A McCartney, L Boni, M Buyse, I Migliaccio, L Biganzoli, A Di LeoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.